New drug combo shows promise for tough ovarian cancers

NCT ID NCT02101775

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive either the drug combo or chemo alone. The goal is to see if the combo can slow tumor growth better than chemo alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Brenner tumor fallopian tube carcinoma fallopian tube neoplasm neoplasm ovarian Brenner tumor ovarian cancer ovarian carcinoma ovarian carcinosarcoma ovarian clear cell cystadenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous cystadenocarcinoma ovarian seromucinous carcinoma ovarian serous cystadenocarcinoma ovarian serous surface papillary adenocarcinoma primary peritoneal carcinoma undifferentiated ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN BRENNER TUMOR OVARIAN CARCINOSARCOMA OVARIAN CLEAR CELL CYSTADENOCARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN MALIGNANT MIXED MESODERMAL (MULLERIAN) TUMOR OVARIAN MUCINOUS CYSTADENOCARCINOMA OVARIAN SEROMUCINOUS CARCINOMA OVARIAN SEROUS CYSTADENOCARCINOMA OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA OVARIAN UNDIFFERENTIATED CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

BCCA-Cancer Centre for the Southern Interior

Kelowna, British Columbia, V1Y 5L3, Canada
BCCA-Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
CHUM - Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, H2X 3E4, Canada
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
City of Hope South Pasadena

South Pasadena, California, 91030, United States
Decatur Memorial Hospital

Decatur, Illinois, 62526, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
London Regional Cancer Program

London, Ontario, N6A 4L6, Canada
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
National University Hospital Singapore

Singapore, 119074, Singapore
Ottawa Hospital and Cancer Center-General Campus

Ottawa, Ontario, K1H 8L6, Canada
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University Health Network Princess Margaret Cancer Center P2C

Toronto, Ontario, M5G 2M9, Canada
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.